Related Experiment Videos
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma
1Department of Urology, Erasmus University, Rotterdam, The Netherlands.
Abstract:
Three antiandrogens are or will soon be available for clinical use. Only Flutamide has been studied in monotherapy of prostatic cancer patients. The use of Flutamide is associated with significant side effects. However, previously potent patients usually remain potent under Flutamide monotherapy. The mechanism of retained potency is poorly understood. In phase II studies parameters which are usually used for determining response of prostatic cancer to endocrine treatment react favourably to Flutamide monotherapy. Since the long-term elevation of plasma testosterone may have an impact on stimulation of prostatic cancer cells, long-term results of studies are mandatory. Such results, unfortunately, are not available in the literature. The use of "pure" antiandrogens as monotherapy and their long-term effectiveness is therefore uncertain. If effectiveness could be proven, especially in comparison to other standard forms of endocrine treatment, the use of a "pure" antiandrogen, especially of a substance with very few side effects, may provide a better quality of life than standard treatment and may therefore be preferable.
Insights
Flutamide monotherapy for prostate cancer shows promise, maintaining patient potency despite side effects. Long-term effectiveness and comparison to other treatments require further study for optimal quality of life.
Area of Science:
- Oncology
- Pharmacology
Background:
- Three antiandrogens are available for clinical use in prostate cancer treatment.
- Flutamide is the only antiandrogen studied in monotherapy for prostate cancer patients.
Purpose of the Study:
- To evaluate the effectiveness and side effects of Flutamide monotherapy in prostate cancer.
- To investigate the mechanism of retained potency in patients treated with Flutamide.
- To assess the long-term impact of Flutamide on prostate cancer and patient quality of life.
Main Methods:
- Phase II studies were conducted to assess treatment response parameters.
- Patient potency was evaluated during Flutamide monotherapy.
Main Results:
- Flutamide monotherapy is associated with significant side effects.
- Previously potent patients generally maintain potency under Flutamide monotherapy.
- Phase II studies indicate favorable responses in prostate cancer treatment parameters with Flutamide.
Conclusions:
- The long-term effectiveness of Flutamide monotherapy and "pure" antiandrogens remains uncertain due to limited long-term data.
- Further long-term studies are mandatory to understand the impact of sustained testosterone elevation on prostate cancer.
- If proven effective and well-tolerated, "pure" antiandrogens may offer a better quality of life for prostate cancer patients compared to standard treatments.